387 studies found for:    biogen | biogen
Show Display Options
Download search resultsDownload the search results for:
biogen | biogen (387 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Biogen Multiple Sclerosis Pregnancy Exposure Registry
Conditions: Multiple Sclerosis;   Exposure During Pregnancy
Interventions: Drug: dimethyl fumarate;   Drug: Peginterferon beta-1a;   Drug: Dalclizumab High Yield Process
2 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
3 Terminated 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
4 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
5 Completed A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
Condition: Healthy
Interventions: Drug: dimethyl fumarate - Reference form;   Drug: dimethyl fumarate - Test form
6 Recruiting An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine
7 Temporarily not available Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Condition: Infantile-onset Spinal Muscular Atrophy (SMA)
Intervention: Drug: nusinersen
8 Terminated Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Lumiliximab + FCR;   Drug: FCR
9 Completed Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants
Condition: Rheumatoid Arthritis
Interventions: Biological: Baminercept alfa 1;   Biological: Placebo;   Biological: Baminercept alfa 2;   Biological: Baminercept alfa 3;   Biological: Baminercept alfa 4;   Biological: Baminercept alfa 5
10 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
11 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
12 Completed A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis
Condition: Exercise
Intervention:
13 Completed
Has Results
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: BG00002 (natalizumab)
14 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a
15 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
16 Recruiting A Study of Multiple Doses of ISIS SMNRx (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Condition: Spinal Muscular Atrophy
Intervention: Drug: ISIS SMNRx (ISIS 396443)
17 Not yet recruiting Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Daclizumab
18 Recruiting Study to Evaluate BIIB059 in CLE With or Without SLE
Conditions: Systemic Lupus Erythematosus (SLE);   Active Cutaneous Lupus Erythematosus (CLE)
Interventions: Drug: BIIB059;   Drug: Placebo
19 Recruiting Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
Conditions: Multiple Sclerosis;   Acute Optic Neuritis
Intervention: Drug: BIIB033 (opicinumab)
20 Recruiting PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
Condition: Trigeminal Neuralgia
Interventions: Drug: BIIB074;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years